Rapidly progressive glomerulonephritis physical examination: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Rapidly progressive glomerulonephritis}}
{{Rapidly progressive glomerulonephritis}}
{{CMG}}; {{AE}} {{AEL}}  
{{CMG}}; {{AE}} {{AEL}} {{N.F}}


==Overview==  
==Overview==  

Revision as of 14:15, 27 July 2018

Rapidly progressive glomerulonephritis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Rapidly progressive glomerulonephritis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray Findings

CT-scan Findings

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Rapidly progressive glomerulonephritis physical examination On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Rapidly progressive glomerulonephritis physical examination

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Rapidly progressive glomerulonephritis physical examination

CDC on Rapidly progressive glomerulonephritis physical examination

Rapidly progressive glomerulonephritis physical examination in the news

Blogs on Rapidly progressive glomerulonephritis physical examination

Directions to Hospitals Treating Rapidly progressive glomerulonephritis

Risk calculators and risk factors for Rapidly progressive glomerulonephritis physical examination

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Elsaiey, MBBCH [2] Nazia Fuad M.D.

Overview

Physical examination

Appearance of the patient

  • Patients with rapidly progressive glomerulonephritis usually appear ill.

Vital signs

  • Hypertension

Skin

  • Leukocytoclastic vasculitis[1]
  • Erythematous nodules due to necrotizing arteritis
  • Granulomatous cutaneous nodules in patients present with granulomatosis with polyangitis

Abdomen

  • Most of patients with ANCA +ve shows gastrointestinal involvement[2]
  • Occult GI bleeding as a result of ulceration due to arteritis
  • Pancreatitis may be present

Neuromuscular

  • Mononeuritis multiplex in ANCA +ve patients[3]
  • Arthritis
  • Arthralgia

Genitourinary

  • Hematuria

References

  1. Daoud MS, Gibson LE, DeRemee RA, Specks U, el-Azhary RA, Su WP (October 1994). "Cutaneous Wegener's granulomatosis: clinical, histopathologic, and immunopathologic features of thirty patients". J. Am. Acad. Dermatol. 31 (4): 605–12. PMID 8089286.
  2. Pagnoux C, Mahr A, Cohen P, Guillevin L (March 2005). "Presentation and outcome of gastrointestinal involvement in systemic necrotizing vasculitides: analysis of 62 patients with polyarteritis nodosa, microscopic polyangiitis, Wegener granulomatosis, Churg-Strauss syndrome, or rheumatoid arthritis-associated vasculitis". Medicine (Baltimore). 84 (2): 115–28. PMID 15758841.
  3. Anadure R, Narayanan C, Varadraj G, Nandeesh B (January 2017). "ANCA Associated Mononeuritis Multiplex with Overlap in Vasculitic Syndromes". J Clin Diagn Res. 11 (1): OD01–OD03. doi:10.7860/JCDR/2017/22252.9149. PMC 5324437. PMID 28273992.

Template:WH Template:WS